Veltis® - Enhancing the body’s natural drug delivery system
Biopharmaceuticals offer several advantages over conventional pharmaceuticals. However, many promising biopharmaceuticals, such as protein and peptides drug candidates fail to produce the desired clinical effect because of rapid inactivation, removal from the body and/or inadequate delivery at site of action. These shortcomings of biologics often result in the requirement for both high and more frequent dosing, with the consequent risk of side effects and reduced treatment compliance.
Our Veltis® technology platform is developed to address these key challenges by leveraging albumin – the human body’s own delivery system. Considered the natural carrier for distribution of pharmaceuticals around the human body, albumin is inherently designed to engage with a range of chemical and biological compounds.
Through subtle modifications to the albumin molecule, we have further enhanced its already remarkable intrinsic characteristics, while preserving its unique biological mechanisms and stable nature. In effect, our Veltis technology platform can transform genetically fused and/or chemically conjugated drugs into more effective, safe and convenient therapeutics.
These therapeutic benefits are achieved through the multiple functional attributes of the pioneering Veltis technology platform:
- Half-life extension: Through an unprecedented high affinity to the neonatal Fc receptor (FcRn), Veltis enables significantly prolonged duration of action of associated compounds, opening the possibilities for enhanced therapeutic effect, while reducing dose frequency.
- Bi-specificity: Coupled with multiple conjugation sites and the possibility for both N- and C-terminal fusion, the Veltis technology platform allows for the creation of bispecific compounds and the possibility to engage multiple targets at once.
- Site-specific delivery: Driven by passive targeting, a preferential accumulation of Veltis associated compounds can be achieved at diseased tissue, such as in inflamed tissue and solid tumors. Through site specific delivery it is possible to maximize dosing without compromising safety.
- Increased payload capacity: Beyond the naturally available thiol-conjugation site on albumin, the Veltis variants offers multiple conjugation sites, providing the opportunity to modulate the drug-to-albumin ratio (DAR) for optimal impact.
Albumin interaction with FcRn receptor
A validated & patent protected technology platform
With more than 30 years of experience with recombinant human albumin and pioneering albumin based technologies, we have created the world’s most extensive patent estate concerning engineered albumin variants; its receptor engagement, manufacturing and related technologies.
Altogether this has enabled the creation of a partnered pipeline of programs at various stages, ranging from discovery to market, and across multiple therapeutic areas. (Pipeline).